Skip to content
Medical Health Aged Care, Science

New study uncovers potential therapeutic target for breast cancer

Centenary Institute 2 mins read

Research conducted at the Centenary Institute has unveiled crucial insights into the underlying molecular mechanisms of breast cancer. The findings could lead to a more effective treatment for the disease, which claims the lives of over 3,000 Australian women and men annually.


The study, involving mice, focused on the role of a protein known as VIRMA in breast tumour growth. Researchers found that abnormally high levels of VIRMA plays a key role in promoting the development of breast cancer cells and is closely associated with poor survival outcomes.


Specifically, the study revealed that a distinct variant of VIRMA, localised within the cell nucleus, is amplified and overexpressed in 15–20% of breast cancers. VIRMA was shown to drive the growth of breast cancer cells by influencing a chemical modification of RNA molecules.


Additionally, the research identified a specific RNA molecule called NEAT1, which interacts with VIRMA and that also promotes the growth of cancer cells.


Dr Justin Wong, Head of the Epigenetics and RNA Biology Program at the Centenary Institute, as well as senior author of the study, expressed his enthusiasm about the research's most exciting observation. He noted that breast cancer cells with elevated levels of VIRMA exhibited heightened susceptibility to death under prolonged stressful conditions. This newfound vulnerability could pave the way for a novel therapeutic strategy to treat breast cancer.


“Based on our findings, we can repurpose certain therapeutic drugs that trigger stress response to target and eliminate breast cancer cells that have high levels of VIRMA. By targeting VIRMA-overexpressing cancer cells, the aim is to enhance stress response in cancer cells and ultimately force them to commit suicide,” said Dr Wong.


Dr Wong added, “Breast cancer remains a pressing public health concern and this research breakthrough provides renewed hope for the development of targeted and impactful treatments.”


The findings of the study were published in the journal Cellular and Molecular Life Science.




Publication: Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response.


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research focuses on three key areas: cancer, inflammation and cardiovascular disease. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.


For more information about the Centenary Institute, visit


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email:

More from this category

  • Medical Health Aged Care
  • 21/06/2024
  • 16:08
Kolmar BNH

Kolmar BNH Sharpens Global Competitiveness with Dual Functionality of HemoHIM

SEOUL, South Korea–BUSINESS WIRE– Kolmar BNH (KOSDAQ: 200130), a leading Original Development Manufacturing (ODM) company for health functional foods, strengthens its market position by…

  • Contains:
  • Medical Health Aged Care
  • 21/06/2024
  • 08:22
Eastern Health

Surgical hub re-opens at Eastern Health Blackburn

Key Messages: Eastern Health Blackburn Public Surgical Centre has reopened and commenced providing services to the community. Closed in 2023 for refurbishment, a large portion of the redevelopment has been completed The facility opens with a updated floorplan boasting onsite pharmacy, specialist clinics and new surgical theatres, which optimise resources for staff and patients. The full development is set to be completed in the coming months. ---------------------------------------------------------------------------------------------------------------------------- DOWNLOAD VIDEO with Lou Ford and Nicole O’Brien ---------------------------------------------------------------------------------------------------------------------------- Eastern Health Blackburn has opened its doors again, providing surgical services to the community. The initial stage of the site redevelopment has utilised the…

  • Medical Health Aged Care
  • 20/06/2024
  • 23:22
C3i Center Inc

C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products

Company awarded commercial Drug Establishment License (DEL) for Canada following successful inspection of C3i’s contract development and manufacturing organization (CDMO) facility. MONTREAL–BUSINESS WIRE– C3i…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.